Open AccessThe serpentine path to a novel mechanism-based inhibitor of acute inflammatory lung injury
Author(s) -
Aron B. Fisher
Publication year - 2014
Publication title -
journal of applied physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.253
H-Index - 229
eISSN - 8750-7587
pISSN - 1522-1601
DOI - 10.1152/japplphysiol.00246.2014
Subject(s) - hyperoxia , lung , phospholipase a2 , medicine , phospholipase , nadph oxidase , pharmacology , lipopolysaccharide , chemistry , oxidative stress , enzyme , biochemistry , immunology
The Comroe lecture on which this review is based described my research path during the past 45 years, beginning with studies of oxidant stress (hyperoxia) and eventuating in the discovery of a synthetic inhibitor of phospholipase A2 activity (called MJ33) that prevents acute lung injury in mice exposed to lipopolysaccharide. In between were studies of lung ischemia, lung surfactant metabolism, the protein peroxiredoxin 6 and its phospholipase A2 activity, and mechanisms for NADPH oxidase activation. These seemingly unrelated research activities provided the nexus for identification of a novel target and a potentially novel therapeutic agent for prevention or treatment of acute lung injury.